Fig. 2.

Bar chart shows hypothetical low-density lipoprotein cholesterol (LDL-C) reductions due to doubling the statin dose, defined according to Weng et al,(16) and adding ezetimibe, defined as 24% based on the IMPROVE-IT study.(15) Data includes only patients treated with lipid-lowering therapy at baseline.